diabetic retinopathy market Overview & Analysis To 2027

1
Diabetic Retinopathy Market to Reach USD 13.04
billion By 2026
2
Factors contributing to high CAGR are growing
prevalence of diabetes along with rising
incidence of blindness. Moreover, increase in
purchasing power and the dread of losing vision
have augmented the expenditure by patients to
avail the indispensable treatment thus, fueling
the overall growth and stability of the diabetic
retinopathy marketMarket Size USD 7.39
billion in 2018, Market Growth CAGR of 7.3,
Market Trends Product Launches and Research for
Advanced Tech Developments Based on current
analysis, the global diabetic retinopathy market
was valued at USD 7.39 billion in 2018 and is
expected to reach USD 13.04 billion by 2026, at a
CAGR of 7.3. Diabetic retinopathy is a diabetes
obstacle that affects eyes. It's caused by damage
to the blood vessels of the light-sensitive
tissue at the back of the eye (retina). Diabetic
retinopathy usually affects both the eyes. As the
condition progresses, diabetic retinopathy
symptoms typically include spots or dark strings
floating in your vision (floaters)blurred vision,
fluctuating vision, impaired color vision, dark
or empty areas in your vision and also vision
loss. Diabetic retinopathy damages the blood
vessels within the retinal tissue, causing them
to leak fluid and distort vision. Excess of sugar
intake in blood can lead to the blockage of the
tiny blood vessels that nourish the retina,
cutting off its blood supply. As a result, the
eye attempts to grow new blood vessels
nonetheless these new blood vessels don't mature
properly and can leak easily. There are two types
of diabetic retinopathy viz, early diabetic
retinopathy and advanced diabetic retinopathy.
Market Summary
www.reportsanddata.com
3

• Further key findings from the report suggest
• Asia-Pacific regional segment of the diabetic
  retinopathy market is expected to register itself
  as highest growing segment during the forecasted
  period, at a CAGR of 8.3 owing it to the
  qualitative as well as quantitative market
  potential offered in developing nations such as
  China India
• Non-proliferative diabetic retinopathy has
  registered highest CAGR of 7.5 and is successful
  in dominating the market with market share of
  56. The most common reason for blindness in
  people suffering from diabetes is
  non-proliferative
• According to the estimates of the screening
  conducted by the All India Ophthalmological
  Society, the prevalence of diabetic retinopathy
  in the data set collected by them was
  approximately calculated to 21.7
• World Health Organization in 2016, estimated that
  1.6 million deaths were directly caused by
  diabetes. WHO estimates that diabetes was the
  seventh leading cause of deaths
• The Diabetic Retinopathy Clinical Research
  Network (DRCR.net) conducts large multi-center
  trials to test new therapies for diabetic eye
  disease, and to compare different therapies. The
  network comprises more than 350 physicians
  practicing at more than 140 clinical sites across
  the country. They are private practice eye
  clinics, enabling the network to quickly bring
  innovative treatments from research into practice
• Approximately 1.5 adults suffering from diabetes
  were affected from proliferative diabetic
  retinopathy in the U.S. in the recent past

4
Market Summary

• Key Players
• Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd.,
  Regeneron Pharmaceuticals Inc., Novartis AG,
  Valeant Pharmaceuticals International Inc.,
  Abbott Laboratories Ltd., Alimera Sciences Inc.,
  AmPio Pharmaceuticals Inc., Bausch Lomb Inc.,
  Boehringer Ingelheim GmbH, iCo Therapeutics Inc.,
  Lupin Ltd., PAREXEL International Corp., Quark
  Pharmaceuticals Inc., Thrombogenic NV, and
  Vitreoretinal Technologies Inc.
• Segmentation
• This report about global diabetic retinopathy
  market forecasts revenue growth at a global,
  regional and country level also, provides an
  analysis on the industry trends in each of the
  sub segments from 2016 to 2026. For the purpose
  of this study, the market is segmented on the
  basis of type, management, distribution channel
  and regions
• Type (Revenue in USD Million 20162026)
• Proliferative diabetic retinopathy
• Non-proliferative diabetic retinopathy
• Mild
• Moderate
• Severe
• Management (Revenue in USD Million 20162026)
• Anti-VEGF
• Intraocular steroid injection
• Laser surgery
• Vitrectomy

To look at the PDF Sample Report and get 30
minutes of a free consultation _at_
https//www.reportsanddata.com/sample-enquiry-form
/1484
www.reportsanddata.com
5
Market Summary

• Distribution channel (Revenue in USD Million
  20162026)
• Eye clinics
• Hospital and pharmacies
• Ambulatory surgical centers
• Other
• Regional Outlook (Revenue in USD Million
  20162026)
• North America
• Europe
• Asia Pacific
• Middle East Africa
• Latin America

Grab Your Report at an Impressive Discount!
Please Click Here https//www.reportsanddata.co
m/make-enquiry-form/1484
www.reportsanddata.com
6
The report emphasizes the following key
questions
Q.1.What are the most lucrative and promising
growth prospects for the market? Q.2.Which
sectors are expected to deliver a high growth
rate and which industry aspects come into play in
this advancement? Q.3.Which geographies are
estimated to exhibit the highest growth and the
underlying causes? Q.4.Which factors are
impacting the future of the market and what are
the driving factors? Q.5.What are the hurdles
and challenges curtailing the industrys growth
in the forecast period?
www.reportsanddata.com
7
About Us
Reports and Data is a market research and
consulting company that provides syndicated
research reports, customized research reports,
and consulting services. Our solutions purely
focus on your purpose to locate, target and
analyze consumer behavior shifts across
demographics, across industries and help clients
make a smarter business decision. We offer market
intelligence studies ensuring relevant and
fact-based research across a multiple industries
including Healthcare, Technology, Chemicals,
Power, and Energy. We consistently update our
research offerings to ensure our clients are
aware about the latest trends existent in the
market. Reports and Data has a strong base of
experienced analysts from varied areas of
expertise.
Contact Us John Watson Head of Business
Development Reports And Data Web
www.reportsanddata.com Direct Line
1-212-710-1370 E-mail sales_at_reportsanddata.com